Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines

Biochemical and Biophysical Research Communications

Volumn 423, Issue 4, 2012, Pages 819-825

  Kakar, Sham S ^a,b   Jala, Venkatakrishna R ^a,b   Fong, Miranda Y ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Cisplatin; Combination treatment; DNA damage; Ovarian cancer; ROS; Withaferin A

Indexed keywords

CISPLATIN; REACTIVE OXYGEN METABOLITE; WITHAFERIN A;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CYTOTOXICITY; DNA DAMAGE; DRUG DNA BINDING; DRUG POTENTIATION; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; FEMALE; HUMANS; OVARIAN NEOPLASMS; REACTIVE OXYGEN SPECIES; WITHANOLIDES;

EID: 84863847870     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.06.047     Document Type: Article

References (38)

1. Pfisterer J., Ledermann J.A. Management of platinum-sensitive recurrent ovarian cancer. Semin. Oncol. 2006, 33:S12-16.
2. Mei L., Chen H., Wei D.M., Fang F., Liu G.J., Xie H.Y., Wang X., Zou J., Han X., Feng D. Maintenance chemotherapy for ovarian cancer. Cochrane Database Syst. Rev. 2010, CD007414.
3. Matsuo K., Lin Y.G., Roman L.D., Sood A.K. Overcoming platinum resistance in ovarian carcinoma. Expert Opin. Investig. Drugs 2010, 19:1339-1354.
4. Galluzzi L., Senovilla L., Vitale I., Michels J., Martins I., Kepp O., Castedo M., Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene 2011.
5. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol. Ther. 1987, 34:155-166.
6. Wozniak K., Czechowska A., Blasiak J. Cisplatin-evoked DNA fragmentation in normal and cancer cells and its modulation by free radical scavengers and the tyrosine kinase inhibitor STI571. Chem. Biol. Interact. 2004, 147:309-318.
7. El-Awady S.E., Moustafa Y.M., Abo-Elmatty D.M., Radwan A. Cisplatin-induced cardiotoxicity Mechanisms and cardioprotective strategies. Eur. J. Pharmacol. 2011, 650:335-341.
8. Kintzel P.E. Anticancer drug-induced kidney disorders. Drug Saf. 2001, 24:19-38.
9. Lieberthal W., Triaca V., Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am. J. Physiol. 1996, 270:F700-708.
10. Lorito G., Hatzopoulos S., Laurell G., Campbell K.C., Petruccelli J., Giordano P., Kochanek K., Sliwa L., Martini A., Skarzynski H. Dose-dependent protection on cisplatin-induced ototoxicity - an electrophysiological study on the effect of three antioxidants in the Sprague-Dawley rat animal model. Med. Sci. Monit. 2011, 17:BR179-186.
11. Donahue R.N., McLaughlin P.J., Zagon I.S. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp. Biol. Med. (Maywood) 2011, 236:883-895.
12. Campbell K.C., Larsen D.L., Meech R.P., Rybak L.P., Hughes L.F. Glutathione ester but not glutathione protects against cisplatin-induced ototoxicity in a rat model. J. Am. Acad. Audiol. 2003, 14:124-133.
13. Nematbakhsh M., Ashrafi F., Safari T., Talebi A., Nasri H., Mortazavi M., Khazaei M., Baradaran-Mahdavi M.M. Administration of vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in rats. J. Nephrol. 2012, 25:410-417.
14. Tuncer S., Dalkilic N., Akif Dunbar M., Keles B. Comparative effects of alpha lipoic acid and melatonin on cisplatin-induced neurotoxicity. Int. J. Neurosci. 2010, 120:655-663.
15. Sanchez-Gonzalez P.D., Lopez-Hernandez F.J., Perez-Barriocanal F., Morales A.I., Lopez-Novoa J.M. Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity. Nephrol. Dial. Transplant. 2011, 26:3484-3495.
16. Yasmeen A., Beauchamp M.C., Piura E., Segal E., Pollak M., Gotlieb W.H. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol. Oncol. 2011, 121:492-498.
17. Rattan R., Graham R.P., Maguire J.L., Giri S., Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 2011, 13:483-491.
18. Yu H.H., Seo S.J., Kim Y.H., Lee H.Y., Park R.K., So H.S., Jang S.L., You Y.O. Protective effect of Rehmannia glutinosa on the cisplatin-induced damage of HEI-OC1 auditory cells through scavenging free radicals. J. Ethnopharmacol. 2006, 107:383-388.
19. Stan S.D., Zeng Y., Singh S.V. Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells. Nutr. Cancer 2008, 60(Suppl 1):51-60.
20. Mohan R., Hammers H.J., Bargagna-Mohan P., Zhan X.H., Herbstritt C.J., Ruiz A., Zhang L., Hanson A.D., Conner B.P., Rougas J., Pribluda V.S. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 2004, 7:115-122.
21. Oh J.H., Kwon T.K. Withaferin A inhibits tumor necrosis factor-alpha-induced expression of cell adhesion molecules by inactivation of Akt and NF-kappaB in human pulmonary epithelial cells. Int. Immunopharmacol. 2009, 9:614-619.
22. Mayola E., Gallerne C., Esposti D.D., Martel C., Pervaiz S., Larue L., Debuire B., Lemoine A., Brenner C., Lemaire C. Withaferin A induces apoptosis in human melanoma cells through generation of reactive oxygen species and down-regulation of Bcl-2. Apoptosis 2011, 16:1014-1027.
23. Koduru S., Kumar R., Srinivasan S., Evers M.B., Damodaran C. Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. Mol. Cancer Ther. 2010, 9:202-210.
24. Srinivasan S., Ranga R.S., Burikhanov R., Han S.S., Chendil D. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res. 2007, 67:246-253.
25. Yu Y., Hamza A., Zhang T., Gu M., Zou P., Newman B., Li Y., Gunatilaka A.A., Zhan C.G., Sun D. Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem. Pharmacol. 2010, 79:542-551.
26. Stan S.D., Hahm E.R., Warin R., Singh S.V. Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res. 2008, 68:7661-7669.
27. Malik F., Kumar A., Bhushan S., Khan S., Bhatia A., Suri K.A., Qazi G.N., Singh J. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound withaferin A with concomitant protection by N-acetyl cysteine. Apoptosis 2007, 12:2115-2133.
28. Lee T.J., Um H.J., Min do S., Park J.W., Choi K.S., Kwon T.K. Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic. Biol. Med. 2009, 46:1639-1649.
29. Munagala R., Kausar H., Munjal C., Gupta R.C. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis 2011, 32:1697-1705.
30. Hamid T., Malik M.T., Kakar S.S. Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells. Mol. Cancer 2005, 4:3.
31. Das A., Durrant D., Mitchell C., Mayton E., Hoke N.N., Salloum F.N., Park M.A., Qureshi I., Lee R., Dent P., Kukreja R.C. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc. Natl. Acad. Sci. USA 2010, 107:18202-18207.
32. Das P.K., Malhotra C.L., Prasad K. Cardiotonic activity of ashwagandhine and ashwagandhinine, two alkaloids from withania ashwagandha, kaul. Arch. Int. Pharmacodyn. Ther. 1964, 150:356-362.
33. Liu L., Yang C., Herzog C., Seth R., Kaushal G.P. Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity. Biochem. Pharmacol. 2010, 79:137-146.
34. Gao J.J., Cai G.Y., Ning Y.C., Liu L., Yang J.R., Dong D., Fu B., Lu Y., Cui S.Y., Chen X.M. DAP5 ameliorates cisplatin-induced apoptosis of renal tubular cells. Am. J. Nephrol. 2012, 35:456-465.
35. Eliopoulos A.G., Kerr D.J., Herod J., Hodgkins L., Krajewski S., Reed J.C., Young L.S. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995, 11:1217-1228.
36. Ravikumar B., Sarkar S., Davies J.E., Futter M., Garcia-Arencibia M., Green-Thompson Z.W., Jimenez-Sanchez M., Korolchuk V.I., Lichtenberg M., Luo S., Massey D.C., Menzies F.M., Moreau K., Narayanan U., Renna M., Siddiqi F.H., Underwood B.R., Winslow A.R., Rubinsztein D.C. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol. Rev. 2010, 90:1383-1435.
37. Mazure N.M., Pouyssegur J. Hypoxia-induced autophagy: cell death or cell survival?. Curr. Opin. Cell Biol. 2010, 22:177-180.
38. Herod J.J., Eliopoulos A.G., Warwick J., Niedobitek G., Young L.S., Kerr D.J. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 1996, 56:2178-2184.